Basal cell carcinoma (BCC) is estimated to be the most common cancer and primarily occurs in light-skinned, older patients. While accurate mortality rates are difficulty to calculate, they are estimated to be low (on the order of 0.12 per 100 000).1 For the vast majority of patients, BCC has an indolent course and an excellent prognosis with standard excision, Mohs surgery, or even topical treatments. These treatments are typically well tolerated, but, like any medical intervention, have risks and carry morbidity. For a variety of reasons, patients sometimes want or need to avoid or delay treatment.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wehner MR. Clinical Evidence on “Watchful Waiting” in Basal Cell Carcinoma. JAMA Dermatol. Published online September 08, 2021. doi:10.1001/jamadermatol.2021.3019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: